Senicapoc

Drug Profile

Senicapoc

Alternative Names: ICA-17043

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Icagen
  • Class Antianaemics; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma

Highest Development Phases

  • Discontinued Allergic asthma; Exercise-induced asthma; Inflammation; Sickle cell anaemia

Most Recent Events

  • 25 Sep 2017 SpringWorks, a Pfizer spinoff is developing senicapoc
  • 25 Sep 2017 SpringWorks Therapeutics plans to assess the potential activity of senicapoc in hereditary xerocytosis
  • 08 Nov 2011 Senicapoc is available for licensing. www.icagen.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top